Skip to main content

Mike Gorenstein, Cronos Group's founder and CEO, speaks during an interview in New York on Sept. 4, 2018.

BRENDAN MCDERMID/Reuters

Part of cannabis and investing

Shares of Cronos Group Inc. fell in Thursday trading after the licensed Canadian cannabis producer announced a wider-than-expected second-quarter loss as costs and expenses rose.

Toronto-based Cronos reported $10.2-million in quarterly revenue before markets opened Thursday, roughly triple the total income generated during the same period in 2018 and well above analyst expectations of $7.3-million. Gross margins came in at 53 per cent, in line with Bay Street estimates.

But Cronos’s adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), revealed a loss of $17.8-million, more than the $10-million loss expected by analysts.

Story continues below advertisement

The company’s TSX-listed stock was trading at $18.51 per share shortly after 12pm ET on Thursday, down 3.4 per cent from its Wednesday closing price.

Costs per gram came in at $3.01 for Q2, representing a 14 per cent increase from $2.63 per gram in Q1, which Cronos blamed on higher processing costs as the company focused more on cannabis oil production.

Other costs at the company soared, with sales and marketing expenses coming in at $5.4-million compared to $364,000 in Q2 of 2018, research and development spending totaling $3.1-million in the quarter versus nothing during the same period last year and administrative expenses nearly quadrupled on a year-over-year basis to $15.2-million.

Earlier this week, Cronos announced a US$300-million mostly cash-based deal to acquire Redwood Holdings, which manufactures, markets and distributes hemp-derived CBD products under the brand Lord Jones. In addition to an ecommerce platform in the United States, Lord Jones products are also sold in 170 Sephora locations.

Late last year, Marlboro cigarette producer Altria Group invested $2.4-billion in Cronos in what remains among the largest-ever transactions in the legal cannabis space. Cronos continues to retain the vast majority of that cash and executives did not provide any specific spending plans in a Thursday morning conference call with analysts.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter